No profile data available.
IN8bio, Inc. (INAB) is a healthcare company in the blood cancer treatment drugs industry, based in New York, United States, with about 18 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$19.44 million. Its market capitalization was $13.21 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
IN8bio reported $0 in revenue for fiscal year 2025.
$13.21 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Marker Therapeutics, Inc. (MRKR), Karyopharm Therapeutics Inc. (KPTI), Cellectar Biosciences, Inc. (CLRB), Aptevo Therapeutics Inc. (APVO).